Alefacept: clinical use in treating psoriasis

References

• Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol.41, 401–407 (1999).
   PubMed Web of Science ®Google Scholar
• Korte J, Sprangers MA, Mombers FM et al. Quality of life in patients with psoriasis: a systematic literature review. J. Investig. Dermatol. Symp. Proc.9, 140–147 (2004).
   PubMedGoogle Scholar
• Fortune DG, Main CJ, O’Sullivan TM et al. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br. J. Dermatol.137(5), 755–60 (1997).
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol.137, 280–284 (2001).
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Invest. Dermatol. Symp. Proc.9, 136–139 (2004).
   PubMed Web of Science ®Google Scholar
• Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol.46, 1–23 (2002).
   PubMed Web of Science ®Google Scholar
• Bos JD, Hagenaars C, Das PK et al. Predominance of memory T cells (CD4+, CDw29+) over naive T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch. Dermatol. Res.281, 24–30 (1989).
   PubMed Web of Science ®Google Scholar
• Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest.98, 1878–1887 (1996).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporine improves psoriasis in a double-blind study. JAMA256, 3110–3116 (1986).
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Jeffes E, McCullough JL. Cytotoxic and immunologic effects of methotrexate in psoriasis. J. Invest. Dermatol.95, 49S–52S (1990).
   Web of Science ®Google Scholar
• Miller GT, Hochman PS, Meier W et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J. Exp. Med.178, 211–222 (1993).
   PubMed Web of Science ®Google Scholar
• Meier W, Gill A, Rogge M et al. Immunomodulation by LFA3TIP, an LFA-3/IgGI fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther. Immunol.2, 159–171 (1995).
   PubMedGoogle Scholar
• Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. J. Immunol.152, 2753–2767 (1994).
   PubMed Web of Science ®Google Scholar
• Sanders ME, Makgoba MW, Sharrow SO et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, Cw29, and Pgp-1) and have enhanced IFN-γ production. J. Immunol.140, 1401–1407 (1988).
   PubMed Web of Science ®Google Scholar
• Majeau GR, Whitty A, Yim K, Meier W, Hochman PS. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation. Cell Adhes. Comm.7, 267–279 (1999).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. The Alefacept Clinical Study Group. N. Engl. J. Med.345(4), 248–255 (2001).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Vaishnaw AK, O’Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T-cell counts. The Alefacept Clinical Study Group. Arch. Dermatol.139, 1563–1570 (2003).
   PubMed Web of Science ®Google Scholar
• Ortonne J-P, Lebwohl M, Griffiths CEM. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Alefacept Clinical Study Group. Eur. J. Dermatol.13, 117–123 (2003).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment psoriasis. Clin. Immunol.105(2), 105–116 (2002).
   PubMed Web of Science ®Google Scholar
• Goedkoop AY, de Rie MA, Picavet DI et al. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch. Dermatol. Res.295, 465–473 (2004).
   PubMed Web of Science ®Google Scholar
• Chamian F, Lowes MA, Lin S-L et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl Acad. Sci. USA102, 2075–2080 (2005).
   PubMed Web of Science ®Google Scholar
• Vaishnaw AK, TenHoor CH. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J. Pharmacokinet. Pharmacodynamics.29(5/6), 415–426 (2003).
   Web of Science ®Google Scholar
• Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. The Alefacept Clinical Study Group. J. Am. Acad. Dermatol.47, 821–833 (2002).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CEM. An international, randomized, double-blind, placebo-controlled Phase III trial of intramuscular alefacept in patients with chronic plaque psoriasis. The Alefacept Clinical Study Group. Arch. Dermatol.139, 719–727 (2003).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br. J. Dermatol.148, 784–788 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J. Drugs. Dermatol.2(6), 624–628 (2003).
   PubMedGoogle Scholar
• Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J. Am. Acad. Dermatol.49, S87–S97 (2003).
   PubMed Web of Science ®Google Scholar
• Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. The Alefacept Clinical Study Group. Dermatology206, 307–315 (2003).
   PubMed Web of Science ®Google Scholar
• Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br. J. Dermatol.150, 317–326 (2004).
   PubMed Web of Science ®Google Scholar
• Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J. Am. Acad. Dermatol.54, 61–63 (2006).
   PubMed Web of Science ®Google Scholar
• Menter MA, Abramovits W. Rational, sequential and combination regimens in the treatment of psoriasis. Dermatol. Ther.11, 88–95 (1999).
   Google Scholar
• Ortonne JP, Khemis A, Koo JYM, Choi J. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venereol.19, 556–563 (2005).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Gottlieb AB, Sweetser M, Ticho B, van de Kerkhof P. International, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. (2006) (submitted).
   Google Scholar
• Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin. Cutan. Med. Surg.24, 37–45 (2005).
   PubMed Web of Science ®Google Scholar
• Myers W, Christiansen L, Gottlieb AB. Treatment of palmoplantar psoriasis with intramuscular alefacept. J. Am. Acad. Dermatol.53, S127–S129 (2005).
   PubMed Web of Science ®Google Scholar
• Cassetty CT, Alexis AF, Shupack JL, Strober BE. Alefacept in the treatment of psoriatic nail disease: a small case series. J. Am. Acad. Dermatol.52, 1101–1102 (2005).
   PubMed Web of Science ®Google Scholar
• Parrish C, Elewski BE, Robbins C, Cantrell, W, Sobera J. The treatment of nail psoriasis with alefacept. Poster presented at ACADEMY 2005, Chicago, IL, (2005).
   Google Scholar
• Fivenson DP, Mathes B. Treatment of generalized lichen planus with alefacept. Arch. Dermatol.142(2), 151–152 (2006).
   PubMed Web of Science ®Google Scholar
• Heffernan MP, Hurley MY, Martin KS et al. Alefacept for alopecia areata. Arch. Dermatol.141(12), 1513–1516 (2005).
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Alefacept: a safety profile. Expert Opin. Drug Safety4(6), 1–11 (2005).
   PubMedGoogle Scholar
• Thaçi D, Pätzold S, Kaufmann R et al. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br. J. Dermatol.152, 1048–1050 (2005).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Casale TB, Frankel E et al. CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J. Am. Acad. Dermatol.49, 816–825 (2003).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Boehncke W-H, Darif M. Safety and efficacy of alefacept in elderly patients and other special populations. J. Drugs Dermatol.4, 718–724 (2005).
   PubMedGoogle Scholar
• Goffe B, Papp K, Gratton D et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin. Ther.27, 1912–1921 (2005).
   PubMed Web of Science ®Google Scholar
• Lynde C, Bulley J, Dakin P. At-home administration of alefacept: the Canadian experience. Poster presented at the 64th annual meeting of the American Academy of Dermatology, San Francisco, CA, USA (2006).
   Google Scholar
• Callen JP, Krueger GG, Lebwohl M et al. AAD consensus statement on psoriasis therapies. J. Am. Acad. Dermatol.49, 897–899 (2003).
   PubMed Web of Science ®Google Scholar
• Guenther L, Langley RG, Shear NH et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. J. Cutan. Med. Surg.8, 321–337 (2004).
   PubMed Web of Science ®Google Scholar
• Sterry W, Barker J, Boehncke W-H et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br. J. Dermatol.151(Suppl. 69), 3–17 (2004).
   PubMed Web of Science ®Google Scholar
• Kraan MC, van Kuijk AWR, Dinant HJ et al. Alefacept treatment in psoriatic arthritis. Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum.46(10), 2776–2784 (2002).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotraxate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum.54(5), 1638–45 (2006).
   PubMed Web of Science ®Google Scholar
• Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J. Am. Acad. Dermatol.53, 73–75 (2005).
   PubMed Web of Science ®Google Scholar
• Sweetser MT, Ticho B, Swan S. Subcutaneous administration of alefacept is bioequivalent to intramuscular administration: results of a randomized, open-label, crossover study in healthy volunteers. Poster presented at the 64th annual meeting of the American Academy of Dermatology, San Francisco, CA, USA (2006).
   Google Scholar
• Stroeber BE. Successful treatment of plaque psoriasis with self-administered subcutaneous alefacept. Arch. Dermatol.141(12), 1602 (2005).
   Google Scholar